Fractyl Health, Inc. (NASDAQ:GUTS) Sees Large Growth in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,570,000 shares, an increase of 16.3% from the December 15th total of 2,210,000 shares. Currently, 12.5% of the shares of the company are sold short. Based on an average trading volume of 330,200 shares, the short-interest ratio is currently 7.8 days.

Insider Activity

In related news, insider Jay David Caplan sold 64,197 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $158,566.59. Following the completion of the transaction, the insider now owns 153,544 shares in the company, valued at approximately $379,253.68. This represents a 29.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $238,396.99. Following the sale, the chief executive officer now owns 491,329 shares of the company’s stock, valued at $1,213,582.63. This trade represents a 16.42 % decrease in their position. The disclosure for this sale can be found here.

Hedge Funds Weigh In On Fractyl Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GUTS. Rhumbline Advisers bought a new stake in shares of Fractyl Health in the second quarter valued at approximately $32,000. Massachusetts Financial Services Co. MA raised its holdings in Fractyl Health by 2.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock valued at $4,255,000 after acquiring an additional 25,829 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Fractyl Health during the second quarter worth $61,000. SG Americas Securities LLC purchased a new stake in shares of Fractyl Health during the third quarter worth $33,000. Finally, Beta Wealth Group Inc. bought a new position in shares of Fractyl Health in the third quarter worth $44,000.

Fractyl Health Stock Performance

Fractyl Health stock traded down $0.01 during trading on Friday, hitting $1.80. The stock had a trading volume of 236,286 shares, compared to its average volume of 265,966. The stock’s 50 day moving average is $2.11 and its two-hundred day moving average is $2.69. Fractyl Health has a 1 year low of $1.74 and a 1 year high of $14.50. The stock has a market cap of $86.58 million and a price-to-earnings ratio of -0.15. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The firm had revenue of $0.01 million for the quarter. As a group, analysts predict that Fractyl Health will post -1.66 EPS for the current year.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.